PT - JOURNAL ARTICLE AU - Marie Breeur AU - Pietro Ferrari AU - Laure Dossus AU - Mazda Jenab AU - Mattias Johansson AU - Sabina Rinaldi AU - Ruth C. Travis AU - Mathilde His AU - Tim J. Key AU - Julie A. Schmidt AU - Kim Overvad AU - Anne Tjønneland AU - Cecilie Kyrø AU - Joseph A. Rothwell AU - Nasser Laouali AU - Gianluca Severi AU - Rudolf Kaaks AU - Verena Katzke AU - Matthias B. Schulze AU - Fabian Eichelmann AU - Domenico Palli AU - Sara Grioni AU - Salvatore Panico AU - Rosario Tumino AU - Carlotta Sacerdote AU - Bas Bueno-de-Mesquita AU - Karina Standahl Olsen AU - Torkjel Manning Sandanger AU - Therese Haugdahl Nøst AU - J. Ramón Quirós AU - Catalina Bonet AU - Miguel Rodríguez Barranco AU - María-Dolores Chirlaque AU - Eva Ardanaz AU - Malte Sandsveden AU - Jonas Manjer AU - Linda Vidman AU - Matilda Rentoft AU - David Muller AU - Kostas Tsilidis AU - Alicia K. Heath AU - Hector Keun AU - Jerzy Adamski AU - Pekka Keski-Rahkonen AU - Augustin Scalbert AU - Marc J. Gunter AU - Vivian Viallon TI - Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition AID - 10.1101/2022.04.11.22273693 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.11.22273693 4099 - http://medrxiv.org/content/early/2022/04/14/2022.04.11.22273693.short 4100 - http://medrxiv.org/content/early/2022/04/14/2022.04.11.22273693.full AB - Background Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations.Methods We analyzed targeted metabolomics data available for 5,828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites, and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data shared lasso penalty.Results Out of the 50 studied metabolites, (i) six were inversely associated with risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2 and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk, and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk.Conclusions These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC).The national cohorts are supported by: Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Geéneérale de l’Education Nationale, Institut National de la Santeé et de la Recherche Meédicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluciéa, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). IDIBELL acknowledges support from the Generalitat de Catalunya through the CERCA Program. The breast cancer study was funded by the French National Cancer Institute (grant number 2015-166). The colorectal cancer studies were funded by World Cancer Research Fund (reference: 2013/1002; www.wcrf.org/), the European Commission (FP7: BBMRI-LPC; reference: 313010; https://ec.europa.eu/). The endometrial cancer study was funded by Cancer Research UK (grant number C19335/A21351). The kidney study was funded by the World Cancer Research Fund (MJ; reference: 2014/1193; www.wcrf.org/) and the European Commission (FP7: BBMRI-LPC; reference: 313010; https://ec.europa.eu/). The liver cancer study was supported in part by the French National Cancer Institute (L’Institut National du Cancer; INCa; grant numbers 2009-139 and 2014-1-RT-02-CIRC-1) and by internal funds of the IARC. For the participants in the prostate cancer study, sample retrieval and preparation, and assays of metabolites were supported by Cancer Research UK (C8221/A19170), and funding for grant 2014/1183 was obtained from the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme. Mathilde His’ work reported here was undertaken during the tenure of a postdoctoral fellowship awarded by the International Agency for Research on Cancer, financed by the Fondation ARC. The funders were not involved in designing the study; collecting, analyzing and interpreting results; or in writing and submitting the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee at the Iinternational Agency for Research on Cancer gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe R scripts developed to implement the analyses will be made available on the GitHub platform, for easy access to all interested scientists. The EPIC data is not publicly available, but access requests can be submitted to the Steering Committee (https://epic.iarc.fr/access/submit_appl_access.php).Adv.PrCadvanced prostate cancerBMIbody mass indexBrCbreast cancerCRCcolorectal cancerCVDcardio-vascular diseasesEnCendometrial cancerEPICEuropean Prospective Investigation into Cancer and nutritionFIAflow injection analysisFDRfalse discovery rateGBCgallbladder and biliary tract cancerHCChepatocellular carcinomaHZMHelmholtz ZentrumIARCInternational Agency for Research on CancerICLImperial College LondonKiCkidney cancerLassoleast absolute shrinkage and selection operatorLCliquid chromatographyLLOQlower limit of quantificationLoc.PrClocalized prostate cancerLODlimit of detectionlysoPClysophosphatidylcholineMS/MStandem mass spectrometryOLSordinary least square regressionORodds ratioPCphosphatidylcholinePCAprincipal component analysisSMsphingomyelinT2Dtype 2 diabetesULOQupper limit of quantification.